about Go Therapeutics
Opening the cancer glycome for better therapeutic targets
GO mines the glycoproteome for cancer-specific epitopes and develops high-affinity antibodies that open access into solid tumors for the next wave of cancer therapies.
GO’s diverse and growing pipeline of cancer-specific targets and antibodies covers a broad range of solid tumor indications. Our validated discovery platform in glycopeptide biology is being utilized in multiple in-house and partnered programs to develop ADCs, CAR Ts, and other next-generation cancer therapies, and precision companion diagnostics to guide patient care.
mission & vision
Closing the solid tumor gap
GO is driven to close the wide gap between hope and reality in the treatment of solid tumors.
Mission & Vision
We are passionately committed to the innovation that drives the translation of glycobiology into advanced cancer therapeutics. We are on the discovery forefront necessary to give advanced cancer therapies clean, open access to solid tumors.
We can do better
The gap between therapeutic hope and therapeutic reality for patients is daunting, but the drug development industry can and must do better. We believe our technology will help bridge that gap for patients across a wide variety of cancer indications.
Opening clean access to solid tumors
Next-generation cancer modalities have been less than successful in solid tumors because they take aim at unsuitable targets. Our super-clean targets will unleash these modalities in solid tumors.
Partnering is a core principle
We want to marry our innovations with the most advanced therapeutic modalities available, and we can’t do that alone. That’s why GO has been partner-focused from the beginning.
Our Story
Mining the cancer glycoproteome for clean targets
GO was founded to close the vast gap between the hope and the clinical reality of advanced cancer treatment.
Next-generation immunotherapies, ADCs, and cell therapies benefit very few patients with solid tumors, leaving the standard of care relatively unchanged for them. GO’s founders realized this gap exists because the targets of these powerful modalities, not the modalities themselves, are unsuitable. New targets – super-clean, potent and broad-spectrum – are needed, and the cancer glycoproteome holds the answers.
That was the genesis of GO: mine the rich cancer glycoproteome universe for new targets and develop antibodies against them that can be turned into the advanced therapeutics we need. Our passion and commitment to innovation is driving the translation of glycobiology into advanced cancer therapeutics. We are on the discovery forefront necessary to give advanced cancer therapies clean, open access to solid tumors.
Leadership
Constantine Theodoropulos
Co-Founder & Chief Executive Officer
Hans Wandall, M.D., Ph.D.
Scientific Co-Founder & Chief Scientific Officer
Aaron C. Groen, Ph.D.
Director of Biology
Constantine Theodoropulos
Co-Founder & Chief Executive Officer
Constantine Theodoropulos co-founded GO Therapeutics in 2014 with the mission to leverage the biology of cancer glycoproteins to create new and powerful cancer therapies.
Constantine has a successful track record as an entrepreneur and advisor to companies on the forefront of life sciences and technology. Prior to GO, Constantine was founder and president of Base Pair Group, a strategic consultancy assisting life science companies on strategy, marketing and business development. He also was a key executive for EBD Group, the leading life science partnering events firm, where he played a key role in EBD’s evolution into the dominant firm facilitating partnering for life science companies, with events generating more than 50,000 partnering meetings each year across three continents. Earlier, he founded Boston Communications, a boutique strategic marketing agency and grew the company into one of the top-rated independent strategic communications agencies serving high technology markets internationally. Mr. Theodoropulos is a frequent advisor to senior executives, boards of directors and venture capitalists. He also raised critical funds and awareness for Dana-Farber Cancer Institute’s Center for Adolescent and Young Adult Oncology in its early stages.
Hans Wandall, M.D., Ph.D.
Scientific Co-Founder & Chief Scientific Officer
Dr. Wandall is co-director of the Center for Glycobiology at the University of Copenhagen. He is a leader in the study of O-glycoproteomics, defining the location of O-glycans in the human proteome and using this information for genetic dissection of glycan functions in epithelial formation, transformation, and carcinogenesis. In cancer, Dr. Wandall’s work focuses on exploiting cancer-associated glycan changes in detecting cancer at an early stage and for the specific targeting of cancer cells with immunotherapies. Dr. Wandall earned his M.D. and Ph.D. from the University of Copenhagen. Dr. Wandall has a broad experience in medicine, cancer-biology, glycobiology, immunology. This includes translational work from Harvard Medical School (Research Fellow in Medicine) and roles within biotech where he served as Director, leading and coordinating clinical trial activities. Also, Dr. Wandall is knowledgeable in managing large research projects with industrial partners. He holds several patents and has published more than 100 peer-reviewed articles in journals, including Nature Medicine, Nature Biotech, Nature Immunology, Nature Protocols, Nature Methods, Developmental Cell, PNAS, Dev Cell, Blood, and Cancer Research.
Aaron C. Groen, Ph.D.
Director of Biology
Dr. Groen brings more than 20 years of experience in therapeutics, protein expression, biochemical systems, and drug characterization. He has held senior research positions at Ohana Biosciences and Unity Biotechnology. He earned his Ph.D. in cell biology at Harvard University, and holds bachelor’s degrees in genetics and psychology from the University of California Berkeley. He is author or co-author on more than 30 peer-reviewed publications. At GO Therapeutics, Dr Groen has led the efforts to demonstrate the translatability of the company’s lead target/antibody programs.
Get In Touch
We always welcome new connections
Contact us to learn more about GO’s science, programs, and partnering opportunities